Paid Clinical Trials New Braunfels
Discover 1,343 paid clinical trials in New Braunfels, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Observational StudyRegistry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
Sponsor:
Axogen Corporation
Location:
Code:
NCT01526681
Conditions
Peripheral Nerve Injuries
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Processed Human Nerve Graft
Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.
Autogenous Nerve Graft
Nerve Tube Conduit
Autologous Breast Reconstruction with Neurotization
Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT05156281
Conditions
Relapsing Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Remibrutinib
Teriflunomide
DAY301To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor:
Day One Biopharmaceuticals, Inc.
Location:
Code:
NCT06752681
Conditions
Advanced or Metastatic Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
DAY301
HFA-152a & HFA-134aA Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
Sponsor:
GlaxoSmithKline
Location:
Code:
NCT06702462
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18 - 45
Healthy Volunteers: Not accepted
Interventions
HFA-152A propellant
HFA-134A propellant
PF-08046054A Study of SGN-PDL1V in Advanced Solid Tumors
Sponsor:
Seagen Inc.
Location:
Code:
NCT05208762
Conditions
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08046054
pembrolizumab
LY3556050A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06074562
Conditions
Diabetic Peripheral Neuropathy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LY3556050
Placebo
Observational StudyContinuous Monitoring and Control of Hypoglycemia
Sponsor:
DexCom, Inc.
Location:
Code:
NCT03340831
Conditions
Diabetes
Eligibility Criteria
Sex: All
Age: 2+
Healthy Volunteers: Not accepted
Interventions
Continuous Glucose Monitoring (CGM)
BIIB091 & DRFA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
Sponsor:
Biogen
Location:
Code:
NCT05798520
Conditions
Relapsing Forms of Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
BIIB091
DRF
Placebo
Single vs. MultipleComparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Sponsor:
Weill Medical College of Cornell University
Location:
Code:
NCT04124120
Conditions
Heart Diseases
Coronary Artery Disease
Coronary Artery Bypass Grafting
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Single arterial graft
Multiple arterial grafting
IMM-1-104A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Sponsor:
Immuneering Corporation
Location:
Code:
NCT05585320
Conditions
Advanced Solid Tumor
Pancreatic Adenocarcinoma
Malignant Melanoma (Cutaneous)
Non-small Cell Lung Cancer (NSCLC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
IMM-1-104 Monotherapy (Treatment Group A)
IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)
IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
IMM-1-104 + dabrafenib (Treatment Group D)
IMM-1-104 + pembrolizumab (Treatment Group E)